RSV Vaccine 97% Effective Against ICU Admissions in Infants

A new immunization against respiratory syncytial virus (RSV) has been rolled out free of charge to all infants in the Canadian provinces of Ontario and Quebec, according to health authorities. The vaccine, part of each province’s universal infant immunization program, has shown strong efficacy in preventing RSV infection and has already led to a marked decline in hospital admissions and intensive care unit (ICU) stays among the youngest patients.

The vaccine, administered in two doses during the first six months of life, targets the virus’s fusion protein, blocking its entry into airway cells. Early data from provincial health departments indicate that RSV‑related hospitalizations have fallen by more than 60 % in the first year of the program, with ICU admissions dropping by a similar margin. Health officials attribute the reduction to the vaccine’s high coverage rate—over 90 % of eligible infants received both doses—and the robust surveillance system that tracks RSV activity across the provinces.

Public health agencies view the program as a significant step forward in reducing the burden of RSV on families and the health care system. Both provinces plan to continue monitoring vaccine effectiveness and to explore expansion of the program to other jurisdictions as data accumulate, aiming to sustain the gains achieved in infant health.